CAS 917389-32-3

Letermovir

Description:

Letermovir is an antiviral medication primarily used for the prevention of cytomegalovirus (CMV) infection in patients undergoing hematopoietic stem cell transplantation. It functions as a selective inhibitor of the CMV terminase complex, which is crucial for viral DNA processing and packaging. Letermovir is characterized by its high specificity for CMV, minimizing the risk of resistance compared to other antiviral agents. The compound is typically administered orally and has a favorable pharmacokinetic profile, allowing for once-daily dosing. Its chemical structure includes a unique combination of functional groups that contribute to its antiviral activity. Letermovir has been shown to effectively reduce the incidence of CMV disease and improve outcomes in at-risk populations. Additionally, it has a relatively low side effect profile, making it a preferred choice in clinical settings. As with any medication, monitoring for potential drug interactions and side effects is essential during treatment. Overall, Letermovir represents a significant advancement in the management of CMV infections in immunocompromised patients.

Formula: C₂₉H₂₈F₄N₄O₄

InChI: InChI=1S/C29H28F4N4O4/c1-40-20-6-3-5-19(16-20)35-11-13-36(14-12-35)28-34-27-21(7-4-8-22(27)30)23(17-26(38)39)37(28)24-15-18(29(31,32)33)9-10-25(24)41-2/h3-10,15-16,23H,11-14,17H2,1-2H3,(H,38,39)/t23-/m0/s1

InChI key: InChIKey=FWYSMLBETOMXAG-QHCPKHFHSA-N

SMILES: C(C(O)=O)[C@@H]1N(C(=NC=2C1=CC=CC2F)N3CCN(CC3)C4=CC(OC)=CC=C4)C5=C(OC)C=CC(C(F)(F)F)=C5

Synonyms:

• (4S)-8-Fluoro-3,4-dihydro-2-[4-(3-methoxyphenyl)-1-piperazinyl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-4-quinazolineacetic acid
• (S)-2-(8-Fluoro-3-(2-methoxy-5-(trifluoromethyl)phenyl)-2-(4-(3-methoxyphenyl)piperazin-1-yl)-3,4-dihydroquinazolin-4-yl)acetic acid
• 4-Quinazolineacetic acid, 8-fluoro-3,4-dihydro-2-[4-(3-methoxyphenyl)-1-piperazinyl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-, (4S)-
• Aic 246
• Prevymis
• Letermovir
• AIC246
• Letermovir (AIC246)
• MK-8828
• CS-2799
• AIC246;AIC 246;AIC-246

Letermovir

CAS: 917389-32-3

Formula: C₂₉H₂₈F₄N₄O₄

Purity: 98%

Color and Shape: Solid

Molecular weight: 572.5506

Ref: IN-DA00GTC7

(S)-2-(8-Fluoro-3-(2-Methoxy-5-(Trifluoromethyl)Phenyl)-2-(4-(3-Methoxyphenyl)Piperazin-1-Yl)-3,4-Dihydroquinazolin-4-Yl)Acetic Acid

CAS: 917389-32-3

(S)-2-(8-Fluoro-3-(2-Methoxy-5-(Trifluoromethyl)Phenyl)-2-(4-(3-Methoxyphenyl)Piperazin-1-Yl)-3,4-Dihydroquinazolin-4-Yl)Acetic Acid

Purity: 98%

Molecular weight: 572.55g/mol

Ref: 54-PC108498

Letermovir

CAS: 917389-32-3

Letermovir

Purity: ≥98%

Molecular weight: 572.55g/mol

Ref: 54-BUP08980

Letermovir

CAS: 917389-32-3

Formula: C₂₉H₂₈F₄N₄O₄

Molecular weight: 572.56

Ref: 4Z-L-141001

Letermovir-d3

CAS: 917389-32-3

Formula: C₂₉H₂₅D₃F₄N₄O₄

Molecular weight: 575.58

Ref: 4Z-L-141011

Letermovir

CAS: 917389-32-3

Letermovir (AIC246) (AIC246) is a novel anti-CMV compound (EC50: about 5 nM in fibroblast cells). It targets the pUL56 subunit of the viral terminase complex.

Formula: C₂₉H₂₈F₄N₄O₄

Purity: 99.85% - 99.87%

Color and Shape: Solid

Molecular weight: 572.55

Ref: TM-T5396

Letermovir-d6

CAS: 917389-32-3

Formula: C₂₉H₂₂D₆F₄N₄O₄

Molecular weight: 578.60

Ref: 4Z-L-141002

Letermovir

CAS: 917389-32-3

Applications Letermovir acts as an orally or i.v administered cytomegalovirus terminus complex inhibitor, antiviral agent, used in the treatment of CMV infection which is prevalent in those with immunocompromised systems.
References Kropeit, D. et al.: Brit. J. Clin Pharmacol., 83, 2678 (2017); Kim, E. et al.: Drugs. 78, 147 (2018);

Formula: C₂₉H₂₈F₄N₄O₄

Color and Shape: Neat

Molecular weight: 572.551

Ref: TR-L321005

Letermovir

CAS: 917389-32-3

Anti-viral; inhibitor of cytomegalovirus-terminase complex

Formula: C₂₉H₂₈F₄N₄O₄

Purity: Min. 98 Area-%

Color and Shape: Yellow Powder

Molecular weight: 572.55 g/mol

Ref: 3D-FL104029

LETERMOVIR

CAS: 917389-32-3

Purity: 98%

Molecular weight: 572.5609741

Ref: 10-F807098